SlideShare a Scribd company logo
1 of 2
Download to read offline
Colon Cancer - Pipeline Review, H1 2014
Global Markets Direct’s, ‘Colon Cancer - Pipeline Review, H1 2014’, provides an overview of the Colon Cancer’s therapeutic
pipeline.
This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued
projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s
team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking
ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Scope
The report provides a snapshot of the global therapeutic landscape of Colon Cancer The report reviews key pipeline products under drug profile section which
includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved
in the therapeutics development for Colon Cancer and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline
projects A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from
company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and
undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Colon Cancer pipeline on the basis of target,
MoA, route of administration and molecule type Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players
with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the
focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Colon Cancer Plan mergers and
acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Colon
Cancer pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with
the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline
table Of Content
introduction
colon Cancer Overview
therapeutics Development
colon Cancer - Therapeutics Under Development By Companies
colon Cancer - Therapeutics Under Investigation By Universities/institutes
colon Cancer - Pipeline Products Glance
colon Cancer - Products Under Development By Companies
colon Cancer - Products Under Investigation By Universities/institutes
colon Cancer - Companies Involved In Therapeutics Development
colon Cancer - Therapeutics Assessment
drug Profiles
colon Cancer - Recent Pipeline Updates
colon Cancer - Dormant Projects
colon Cancer - Discontinued Products
colon Cancer - Product Development Milestones
appendix
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Colon Cancer - Pipeline Review, H1 2014
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Colon Cancer - Pipeline Review, H1 2014

More Related Content

More from Ambikabasa

Arrhythmias pipeline review, h1 2015
Arrhythmias   pipeline review, h1 2015Arrhythmias   pipeline review, h1 2015
Arrhythmias pipeline review, h1 2015Ambikabasa
 
Ocular pain pipeline review, h1 2015
Ocular pain   pipeline review, h1 2015Ocular pain   pipeline review, h1 2015
Ocular pain pipeline review, h1 2015Ambikabasa
 
Paroxysmal nocturnal hemoglobinuria pipeline review, h1 2015
Paroxysmal nocturnal hemoglobinuria   pipeline review, h1 2015Paroxysmal nocturnal hemoglobinuria   pipeline review, h1 2015
Paroxysmal nocturnal hemoglobinuria pipeline review, h1 2015Ambikabasa
 
Rhabdomyosarcoma pipeline review, h1 2015
Rhabdomyosarcoma   pipeline review, h1 2015Rhabdomyosarcoma   pipeline review, h1 2015
Rhabdomyosarcoma pipeline review, h1 2015Ambikabasa
 
Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015Ambikabasa
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015Ambikabasa
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015Ambikabasa
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015Ambikabasa
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015Ambikabasa
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015Ambikabasa
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015Ambikabasa
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015Ambikabasa
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015Ambikabasa
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015Ambikabasa
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015Ambikabasa
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015Ambikabasa
 
Co mentis, inc. product pipeline review - 2015
Co mentis, inc.   product pipeline review - 2015Co mentis, inc.   product pipeline review - 2015
Co mentis, inc. product pipeline review - 2015Ambikabasa
 
Therapure biopharma inc. product pipeline review - 2015
Therapure biopharma inc.   product pipeline review - 2015Therapure biopharma inc.   product pipeline review - 2015
Therapure biopharma inc. product pipeline review - 2015Ambikabasa
 
Genzyme corporation product pipeline review - 2015
Genzyme corporation   product pipeline review - 2015Genzyme corporation   product pipeline review - 2015
Genzyme corporation product pipeline review - 2015Ambikabasa
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015Ambikabasa
 

More from Ambikabasa (20)

Arrhythmias pipeline review, h1 2015
Arrhythmias   pipeline review, h1 2015Arrhythmias   pipeline review, h1 2015
Arrhythmias pipeline review, h1 2015
 
Ocular pain pipeline review, h1 2015
Ocular pain   pipeline review, h1 2015Ocular pain   pipeline review, h1 2015
Ocular pain pipeline review, h1 2015
 
Paroxysmal nocturnal hemoglobinuria pipeline review, h1 2015
Paroxysmal nocturnal hemoglobinuria   pipeline review, h1 2015Paroxysmal nocturnal hemoglobinuria   pipeline review, h1 2015
Paroxysmal nocturnal hemoglobinuria pipeline review, h1 2015
 
Rhabdomyosarcoma pipeline review, h1 2015
Rhabdomyosarcoma   pipeline review, h1 2015Rhabdomyosarcoma   pipeline review, h1 2015
Rhabdomyosarcoma pipeline review, h1 2015
 
Raynauds disease pipeline review, h1 2015
Raynauds disease   pipeline review, h1 2015Raynauds disease   pipeline review, h1 2015
Raynauds disease pipeline review, h1 2015
 
Travelers diarrhea pipeline review, h1 2015
Travelers diarrhea   pipeline review, h1 2015Travelers diarrhea   pipeline review, h1 2015
Travelers diarrhea pipeline review, h1 2015
 
Herpes zoster (shingles) pipeline review, h1 2015
Herpes zoster (shingles)   pipeline review, h1 2015Herpes zoster (shingles)   pipeline review, h1 2015
Herpes zoster (shingles) pipeline review, h1 2015
 
Emphysema pipeline review, h1 2015
Emphysema   pipeline review, h1 2015Emphysema   pipeline review, h1 2015
Emphysema pipeline review, h1 2015
 
Cerebral infarction (brain infarction) pipeline review, h1 2015
Cerebral infarction (brain infarction)   pipeline review, h1 2015Cerebral infarction (brain infarction)   pipeline review, h1 2015
Cerebral infarction (brain infarction) pipeline review, h1 2015
 
Seborrhea pipeline review, h1 2015
Seborrhea   pipeline review, h1 2015Seborrhea   pipeline review, h1 2015
Seborrhea pipeline review, h1 2015
 
Respiratory depression pipeline review, h1 2015
Respiratory depression   pipeline review, h1 2015Respiratory depression   pipeline review, h1 2015
Respiratory depression pipeline review, h1 2015
 
H1 n1 infection pipeline review, h1 2015
H1 n1 infection   pipeline review, h1 2015H1 n1 infection   pipeline review, h1 2015
H1 n1 infection pipeline review, h1 2015
 
Nicotine addiction pipeline review, h1 2015
Nicotine addiction   pipeline review, h1 2015Nicotine addiction   pipeline review, h1 2015
Nicotine addiction pipeline review, h1 2015
 
Food allergy pipeline review, h1 2015
Food allergy   pipeline review, h1 2015Food allergy   pipeline review, h1 2015
Food allergy pipeline review, h1 2015
 
Uveal melanoma pipeline review, h1 2015
Uveal melanoma   pipeline review, h1 2015Uveal melanoma   pipeline review, h1 2015
Uveal melanoma pipeline review, h1 2015
 
Tillotts pharma ag product pipeline review - 2015
Tillotts pharma ag   product pipeline review - 2015Tillotts pharma ag   product pipeline review - 2015
Tillotts pharma ag product pipeline review - 2015
 
Co mentis, inc. product pipeline review - 2015
Co mentis, inc.   product pipeline review - 2015Co mentis, inc.   product pipeline review - 2015
Co mentis, inc. product pipeline review - 2015
 
Therapure biopharma inc. product pipeline review - 2015
Therapure biopharma inc.   product pipeline review - 2015Therapure biopharma inc.   product pipeline review - 2015
Therapure biopharma inc. product pipeline review - 2015
 
Genzyme corporation product pipeline review - 2015
Genzyme corporation   product pipeline review - 2015Genzyme corporation   product pipeline review - 2015
Genzyme corporation product pipeline review - 2015
 
Quantum genomics sa product pipeline review - 2015
Quantum genomics sa   product pipeline review - 2015Quantum genomics sa   product pipeline review - 2015
Quantum genomics sa product pipeline review - 2015
 

Recently uploaded

Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMVoces Mineras
 
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
8447779800, Low rate Call girls in Uttam Nagar Delhi NCRashishs7044
 
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?Olivia Kresic
 
Annual General Meeting Presentation Slides
Annual General Meeting Presentation SlidesAnnual General Meeting Presentation Slides
Annual General Meeting Presentation SlidesKeppelCorporation
 
Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionMintel Group
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfJos Voskuil
 
Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Seta Wicaksana
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCRashishs7044
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...ictsugar
 
Islamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in IslamabadIslamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in IslamabadAyesha Khan
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Anamaria Contreras
 
India Consumer 2024 Redacted Sample Report
India Consumer 2024 Redacted Sample ReportIndia Consumer 2024 Redacted Sample Report
India Consumer 2024 Redacted Sample ReportMintel Group
 
Innovation Conference 5th March 2024.pdf
Innovation Conference 5th March 2024.pdfInnovation Conference 5th March 2024.pdf
Innovation Conference 5th March 2024.pdfrichard876048
 
Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Kirill Klimov
 
APRIL2024_UKRAINE_xml_0000000000000 .pdf
APRIL2024_UKRAINE_xml_0000000000000 .pdfAPRIL2024_UKRAINE_xml_0000000000000 .pdf
APRIL2024_UKRAINE_xml_0000000000000 .pdfRbc Rbcua
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationAnamaria Contreras
 

Recently uploaded (20)

Memorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQMMemorándum de Entendimiento (MoU) entre Codelco y SQM
Memorándum de Entendimiento (MoU) entre Codelco y SQM
 
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
8447779800, Low rate Call girls in Uttam Nagar Delhi NCR
 
MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?MAHA Global and IPR: Do Actions Speak Louder Than Words?
MAHA Global and IPR: Do Actions Speak Louder Than Words?
 
Annual General Meeting Presentation Slides
Annual General Meeting Presentation SlidesAnnual General Meeting Presentation Slides
Annual General Meeting Presentation Slides
 
Future Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted VersionFuture Of Sample Report 2024 | Redacted Version
Future Of Sample Report 2024 | Redacted Version
 
No-1 Call Girls In Goa 93193 VIP 73153 Escort service In North Goa Panaji, Ca...
No-1 Call Girls In Goa 93193 VIP 73153 Escort service In North Goa Panaji, Ca...No-1 Call Girls In Goa 93193 VIP 73153 Escort service In North Goa Panaji, Ca...
No-1 Call Girls In Goa 93193 VIP 73153 Escort service In North Goa Panaji, Ca...
 
Digital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdfDigital Transformation in the PLM domain - distrib.pdf
Digital Transformation in the PLM domain - distrib.pdf
 
Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...Ten Organizational Design Models to align structure and operations to busines...
Ten Organizational Design Models to align structure and operations to busines...
 
Call Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North GoaCall Us ➥9319373153▻Call Girls In North Goa
Call Us ➥9319373153▻Call Girls In North Goa
 
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
8447779800, Low rate Call girls in Shivaji Enclave Delhi NCR
 
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...Global Scenario On Sustainable  and Resilient Coconut Industry by Dr. Jelfina...
Global Scenario On Sustainable and Resilient Coconut Industry by Dr. Jelfina...
 
Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)Japan IT Week 2024 Brochure by 47Billion (English)
Japan IT Week 2024 Brochure by 47Billion (English)
 
Islamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in IslamabadIslamabad Escorts | Call 03070433345 | Escort Service in Islamabad
Islamabad Escorts | Call 03070433345 | Escort Service in Islamabad
 
Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.Traction part 2 - EOS Model JAX Bridges.
Traction part 2 - EOS Model JAX Bridges.
 
Corporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information TechnologyCorporate Profile 47Billion Information Technology
Corporate Profile 47Billion Information Technology
 
India Consumer 2024 Redacted Sample Report
India Consumer 2024 Redacted Sample ReportIndia Consumer 2024 Redacted Sample Report
India Consumer 2024 Redacted Sample Report
 
Innovation Conference 5th March 2024.pdf
Innovation Conference 5th March 2024.pdfInnovation Conference 5th March 2024.pdf
Innovation Conference 5th March 2024.pdf
 
Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024Flow Your Strategy at Flight Levels Day 2024
Flow Your Strategy at Flight Levels Day 2024
 
APRIL2024_UKRAINE_xml_0000000000000 .pdf
APRIL2024_UKRAINE_xml_0000000000000 .pdfAPRIL2024_UKRAINE_xml_0000000000000 .pdf
APRIL2024_UKRAINE_xml_0000000000000 .pdf
 
PSCC - Capability Statement Presentation
PSCC - Capability Statement PresentationPSCC - Capability Statement Presentation
PSCC - Capability Statement Presentation
 

Colon cancer pipeline review, h1 2014

  • 1. Colon Cancer - Pipeline Review, H1 2014 Global Markets Direct’s, ‘Colon Cancer - Pipeline Review, H1 2014’, provides an overview of the Colon Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Colon Cancer The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Colon Cancer and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Colon Cancer pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Colon Cancer Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Content introduction colon Cancer Overview therapeutics Development colon Cancer - Therapeutics Under Development By Companies colon Cancer - Therapeutics Under Investigation By Universities/institutes colon Cancer - Pipeline Products Glance colon Cancer - Products Under Development By Companies colon Cancer - Products Under Investigation By Universities/institutes colon Cancer - Companies Involved In Therapeutics Development colon Cancer - Therapeutics Assessment drug Profiles colon Cancer - Recent Pipeline Updates colon Cancer - Dormant Projects colon Cancer - Discontinued Products colon Cancer - Product Development Milestones appendix ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Colon Cancer - Pipeline Review, H1 2014
  • 2. Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Colon Cancer - Pipeline Review, H1 2014